Our Pipeline

Robust Pipeline Focused on Advancing ROCK Inhibitor Portfolio

Our Pipeline

Target/Product

Indications

Research

Preclinical

Phase 1

Phase 2

Upcoming Milestones

ROCK Portfolio

Idiopathic pulmonary fibrosis (IPF)

Phase 2a topline data –
H1 2024

ROCK2 Selective Inhibitor
zelasudil (RXC007)

Pancreatic cancer*

Phase 1b commence –
2024

cGvHD*

Phase 2a commence –
2024

Fibrostenotic Crohn’s Disease

CTA submission –
H2 2023

Programmes for Partnership

Genetically selected MSS mCRCrnBiliary tract cancer and pancreatic cancer

Recruitment Closed
Data report – H1 2024

Discoidin Domain Receptor (DDR) Inhibitor
(RXC009)

Fibrosis, cancer-associated fibrosis

IND / CTA Submission

KRAS Inhibitor
(G12D selective and multi)

Oncology

DC nomination

Partnered

Idiopathic pulmonary fibrosis (IPF)

Licensed to AstraZeneca

Oncology

Sold to Jazz

MAPK Pathway Target

Oncology

Licensed to Jazz

GI: Gastrointestinal; IND: Investigational new drug application; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; RAF: Rapidly accelerated fibrosarcoma; ROCK: Rho associated protein kinase; cGvHD: Chronic Graft Versus Host Disease
* Would require additional funding

ROCK Portfolio
Phase 2

Idiopathic pulmonary fibrosis (IPF)

UPCOMING MILESTONES

Phase 2a topline data –
H1 2024

ROCK2 Selective Inhibitor
zelasudil (RXC007)

Preclinical

Pancreatic cancer*

UPCOMING MILESTONES

Phase 1b commence –
2024

Preclinical

cGvHD*

UPCOMING MILESTONES

Phase 2a commence –
2024

Preclinical

Fibrostenotic Crohn’s Disease

UPCOMING MILESTONES

CTA submission –
H2 2023

Programmes for Partnership
Phase 2

Genetically selected MSS mCRCrnBiliary tract cancer and pancreatic cancer

UPCOMING MILESTONES

Recruitment Closed
Data report – H1 2024

Discoidin Domain Receptor (DDR) Inhibitor
(RXC009)

Preclinical

Fibrosis, cancer-associated fibrosis

UPCOMING MILESTONES

IND / CTA Submission

KRAS Inhibitor
(G12D selective and multi)

Research

Oncology

UPCOMING MILESTONES

DC nomination

Partnered
Phase 1

Idiopathic pulmonary fibrosis (IPF)

UPCOMING MILESTONES

Licensed to AstraZeneca

UPCOMING MILESTONES

Sold to Jazz

MAPK Pathway Target

Research

Oncology

UPCOMING MILESTONES

Licensed to Jazz

GI: Gastrointestinal; IND: Investigational new drug application; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; RAF: Rapidly accelerated fibrosarcoma; ROCK: Rho associated protein kinase; cGvHD: Chronic Graft Versus Host Disease
* Would require additional funding